Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02315586 · ClinicalTrials.gov registry record
Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
A clinical trial of Idiopathic Pulmonary Fibrosis, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 63
- Enrollment target
- 1
- Study location
NCT02315586 is a study of Idiopathic Pulmonary Fibrosis that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 63 participants, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02315586, a study of Idiopathic Pulmonary Fibrosis, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that becomes worse over time. There is currently no effective treatment for it. Researchers want to study the disease and learn new ways to treat it. Objectives: \- To discover new pathways that are involved in pulmonary fibrosis. To develop new drugs that may be used to treat pulmonary fibrosis. Eligibility: * People at least 18 years old with IPF. * Healthy volunteers at least 18 years old. Design: * Participants will be screened with medical history, questionnaire, and physical exam. They will have blood, lung, and walking tests and chest scans. * All participants will have 1 study visit, including: * Medical history and physical exam. * Questions about their breathing. * Blood tests. * Breathing tests. * Six-minute walk test. * Pregnancy test. * Chest x-ray (healthy volunteers) or chest CT scan (people with pulmonary fibrosis ). * Small area of skin may be removed. * Genetic tests of blood and skin samples. Participants will probably not be informed of any findings. Samples may be used to make stem cells for use in research. Participants may be contacted in the future to give consent for this research. * Some participants will have repeat visits over many years, repeating many of the study tests.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2015-01-28 |
| Est. Completion | 2022-02-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02315586
The ClinicalTrials.gov registry entry for NCT02315586 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (92% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT02315586 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02315586 about?
NCT02315586 is a clinical study titled "Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis". Background: \- Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that becomes worse over time. There is currently no effective treatment for it. Researchers want to study the disease and learn new ways to treat it. Objectives: \- To discover new pathways that are involved in pulmonary...
What is the current status of trial NCT02315586?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2015-01-28. Estimated completion is 2022-02-23.
What conditions does trial NCT02315586 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
Who is sponsoring clinical trial NCT02315586?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02315586 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.